116 results about "Felodipine" patented technology

A pharmaceutical composition comprising a solid unit dosage form comprising: one or more of pharmaceutically active ingredients selected from valacyclovir, olanzapine, voriconazole, topotecan, artesunate, amodiaquine, guggulosterone, ramipril, telmisartan, tibolone, atorvastatin, simvastatin, amlodipine, ezetimibe, fenofibrate, tacrolimus, valgancyclovir, valsartan, clopidrogel, estradiol, trenbolone, efavirenz, metformin, pseudoephedrine, verapamil, felodipine, valproic acid/sodium valproate, mesalamine, hydrochlorothiazide, levosulpiride, nelfinavir, cefixime and cefpodoxime proxetil in combination with a water insoluble polymer and/or a water soluble polymer. Methods for making the pharmaceutical composition are also disclosed.

The present invention discloses a felodipine control-released preparation. It comprises core body and film. Said core body comprises feldodipine with effective therapeutic dose and physiologically-acceptable osmotic pressure regulating agent, osmotic accelerator and adhesive, and its film is made up by using semipermeable membrane material and pore-forming material.

The invention provides a preparation method of a sustained-release preparation containing felodipine. The invention is characterized in that the felodipine and bond are dissolved in ethanol absolute solution or water solution containing more than 60 percent ethanol, then are fixed with matrix sustained-release necessities and filling agent and finally are moistened and granulated by the ethanol absolute solution or the water solution of ethanol. The invention also provides the sustained-release preparation prepared by the method and usage in preparation of medicine for treating hypertension.

The double layer osmotic pump controlled release felodipine medicine composition includes double layer core and coating film. The double layer core contains felodipine and pharmaceutically acceptable excipient; and the coating film is semi-permeating film with or without pore creating agent. The double layer osmotic pump controlled release felodipine medicine composition of the present invention can control the release of medicine in some specific time period, has reduced medicine taking times, smooth in vivo blood medicine concentration and radically raised medicine safety and effectiveness.

The invention provides a pharmaceutical composition which comprises calcium channel blockers of a medicinal dose, angiotensin II receptor antagonists of a medicinal dose, one or more of B vitamins of a medicinal dose and pharmaceutically acceptable carriers, wherein the calcium channel blockers are selected from amlodipine, felodipine, israbipine, nicardipine, nifedipine, nisoldipine, nitrendipine, lacidipine, diltiazem or verapamil; the angiotensin II receptor antagonists are selected from candesartan, telmisartan, losartan, valsartan, irbesartan, eprosartan, tasosartan or olmesartan; and the B vitamins are selected from one or more of vitamin B6, vitamin B12, folic acid and calcium leucovorin. The pharmaceutical composition of the invention can improve the curative effect of the hypotensor, enhance the target organ protecting action of the hypotensor, and reduce the morbidity of complications of angina, myocardial infarction and the like.

The invention relates to a hypotensor felodipine pharmaceutical composition and a preparation method thereof. The composition comprises felodipine, a dispersing agent, a filling agent, a disintegrating agent, a solubilizing agent, a lubricant and a dry adhesive. The preparation method of the composition comprises the steps of: firstly, micronizing the felodipine with the dispersing agent, and then carrying out dry process granulation to prepare a felodipine pharmaceutical preparation. In the preparation method, the water and organic solvent are not used, the moist heat process and production energy consumption are reduced, and the quality control in the production process is facilitated. The felodipine pharmaceutical preparation prepared with the preparation method provided by the invention is uniform in content and good in dissolution rate.

The invention discloses a preparation method of felodipine sustained release tablets. The method is characterized by comprising the following steps of: mixing felodipine accounting for 1-10 percent of the total component weight, a part of hydroxypropyl methylcellulose accounting for 20-55 percent of the total component weight and a filler; and wetting by using a wetting agent to carry out wet granulation; after wet granules are dried at low temperature, mixing the dried granules with residual hydroxypropyl methylcellulose; adding a lubricating agent and then tabletting to prepare cores containing main drugs; and coating by using a coating material to obtain the felodipine sustained release tablets. The preparation method is easy to control and suitable for industrial scale production, has high product yield and reduces the production cost. Compared with merchant like preparations, the felodipine sustained release tablets obtained by using the preparation method has similar in vitro release curve.

The invention discloses a composition containing a dihydropyridine calcium channel blocker and a preparation method thereof and relates to a sustained-release preparation of felodipine, which comprises felodipine which is dihydropyridine calcium channel blocker and function as an active ingredient, enalapril which is angiotensin converting enzyme inhibitor, as well as a slow release material, a filling agent and a lubricating agent which function as auxiliary materials; wherein the slow release material contains hydroxypropyl methylcellulose. As the enalapril which is angiotensin converting enzyme inhibitor is added in coating solution, the curative effect of the sustained-release preparation is improved.

The invention provides a controlled release preparation and a preparation method thereof. The controller release preparation is characterized in that dual-layer osmotic pump tablet semi-permeable membrane is covered by a drug-containing coating layer which can rapidly release partial drug active constituent of marked dosage; and a dual-layer osmotic pump tablet core is formed by two layers, one layer contains most drug active constituent of the marked dosage and permeation enhancing substances, the other layer contains permeable substances, the tablet core is covered by the semi-permeable membrane containing polymers, and a small hole is arranged on the semi-permeable membrane on the side of a drug-containing active constituent layer. The controlled release preparation solves the problem that the release of the dual-layer osmotic pump tablet in vitro and in vivo is lagged behind for 1-3 hour, and can reduce the incomplete release of the active constituent. The preparation method of the controlled release preparation comprises the following steps that the drug active constituent accounting for large part of the marked content is prepared in the dual-layer tablet and then the rest drug active constituent is covered in the coating layer of the dual-layer tablet. Preferably, felodipine is selected as the drug active constituent.

The present invention provides slow-release tablets containing felodipine and a metoprolo salt, and a preparation method thereof. The slow-release tablets comprise a tablet core, a drug-containing layer, a slow-release coating layer and a film coating layer from the inside to the outside, wherein the tablet core is prepared by tableting a metoprolol salt, an insoluble slow-release framework material, and other pharmaceutically-acceptable excipients, and the drug-containing layer comprises micronized felodipine, a solubilizing agent and a binder. According to the present invention, the process is simple and feasible, the characteristic of 24-hour continuous release is provided, the direct tablet core coating manner is adopted to prepare the slow-release tablet, the production process can be completed in the traditional production workshop, and disadvantage of requirement of the fluidized bed and other equipment in the original process is overcome.

The invention discloses a felodipine-containing sustained-release preparation, which comprises a tablet core and a thin film, wherein the inside of the tablet core contains an effective curative dose of felodipine and a physiologically acceptable pharmaceutic adjuvant. The sustained-release preparation is characterized by consisting of the felodipine, a sustained-release material, a bulking agent, an adhesive, a coloring agent, a lubricant, a wetting agent and a film-forming material. The sustained-release preparation prepared can control drug release effectively to achieve ideal treatment effect, enable human bodies to obtain stable treated blood concentration and optimize the curative effect dose.

The invention relates to a medicinal composition containing Enalapril or Enalapril-acid addition salt and Felodipine, prepared by putting slow-release pellets containing Felodipine and quick-release pellets containing Enalapril or Enalapril-acid addition salt in capsules. Each dosage unit of the medicinal composition contains 2.5-25mg of Enalapril maleate and 2.5-25mg of Felodipine. The medicinal composition can stabilize blood pressure quickly, and keep effective blood concentration for 24 hours, with increasing patient compliance. The medicinal composition is administered only once a day.

The invention discloses felodipine slow-release microspheres which consist of felodipine, ethylene cellulose and a drug release regulator and are prepared by adopting a W1/O/W2 emulsification method, and the mass percentages of the felodipine, the ethylene cellulose and the drug release regulator are respectively 1-50, 36-99 and 0-44. The felodipine slow-release microspheres prepared in the invention adopt an in-vitro release condition of felodipine slow-release tablets in the United States Pharmacopeia (USP) and can slowly release drugs in 24 hours in vitro drug release, and compared with a felodipine dug suspension and felodipine slow-release microspheres prepared by an O/W method, the blood concentration and the oral bioavailability in vivo by adopting the felodipine slow-release microspheres prepared in the invention released are improved.

A method and composition are provided for the treatment of an anorectal disorder and for controlling the pain associated therewith. The method comprises administering to a subject in need of such treatment therapeutically effective amounts of a calcium channel blocker either alone or together with a nitric oxide donor. Amlodipine, anipamil, barnidipine, benidipine, bepridil, darodipine, diltiazem, efonidipine, felodipine, isradipine, lacidipine, lercanidipine, lidoflazine, manidipine, mepirodipine, nicardipine, nifedipine, niludipine, nilvadipine, nimodipine, nisoldipine, nitrendipine, perhexiline, tiapamil, verapamil and pharmaceutically acceptable salts thereof, are suitable calcium channel blockers.

The invention discloses a compound sustained-release preparation containing felodipine and ramipril and a preparation method of the compound sustained-release preparation, wherein the compound sustained-release preparation is prepared by mixing felodipine sustained-release pellets and ramipril immediate-release pellets according to a specific dose proportion. The felodipine sustained-release pellets can sustainably release for 12 hours, and can be taken once a day, so as to keep the antihypertensive effect for a long time, the ramipril immediate-release pellets can be quickly absorbed so as to achieve the antihypertensive effect and treat the plasma concentration, due to the combination of the two kinds of pellets, the antihypertensive effect can be greatly enhanced, the toxic and side effect of the medicine can be reduced, the administration frequency can be reduced, sustainably stable antihypertensive effect can be achieved in a human body, the patient compliance can be enhanced, the compound sustained-release preparation consists of hundreds and thousands of pellets in uniform particle sizes, so that the damage of individual pellets will not cause burst release of the whole preparation, and compared with the sustained release tablets, the compound sustained-release preparation disclosed by the invention has the advantages of higher safety, lower irritation to gastrointestinal tract, more stable plasma concentration and capability of effectively improving the clinical effect.

The invention discloses a medicine composite for treating and relieving high blood pressure and a preparation method thereof. The composite comprises 10-320mg of telmisartan and 1-20mg of felodipine slow-release preparation. The composite is used for treating patients with moderate and acute high blood pressure and patients whose blood pressure can not be adequately controlled after the high blood pressure is treated by an angiotensin II receptor antagonist or a calcium antagonist.

The present invention belongs to the field of pharmaceutical preparations, and relates to a single layer osmotic pump controlled release preparation containing metoprolol and felodipine. Specifically the controlled release preparation comprises a tablet core and a semipermeable film coating, wherein the tablet core comprises the following components, by weight, 50-100 parts of metoprolol or a pharmaceutically acceptable salt thereof, 5-10 parts of felodipine, 3-10 parts of hydroxy propyl methyl cellulose, 5-25 parts of povidone, and 5-25 parts of sodium carboxymethyl cellulose. The present invention further relates to a preparation method and a use of the preparation. With the controlled release preparation of the present invention, synchronous and constant speed release of metoprolol and felodipine can be achieved. Compared with preparation of double layer osmotic pump tablets, the preparation method of the present invention has a characteristic of substantial simplification of the preparation process, wherein the method comprises that metoprolol is encapsulated in a pill core, and then conjointly preparing into tablets with felodipine.

A method of effectively treating hypertension in humans is achieved by administering felodipine via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours days, and preferably for about 3 to about 8 days.

The invention discloses a Felodipine sustained-release tablet and a method for controlling the sustained-release of the Felodipine sustained-release tablet. The Felodipine sustained-release tablet comprises Felodipine and HPMC high polymer material, the Felodipine accounts for 2.0-7.0% of the total sum of the granules or the powder, wherein, the viscosity range of the granules or the powder of the prepared Felodipine sustained-release tablet is respectively 2000-2400 centipoise and 6840-7240centipoise. The Felodipine sustained-release tablet has quality conforming to the standard and similar release property with the preparation of the same type sold in markets, and the quality control is carried out before production, thus reducing re-doing, saving production cost, reducing energy consumption and improving productivity.